Risk factors for developing polycythemia vera (PV) are discussed by Aaron Gerds, MD, MS. Aaron Gerds, MD, MS: Hi. Welcome to this discussion of the updated NCCN [National Comprehensive Cancer Network] ...

PV management requires balancing thrombotic risk reduction with quality of life preservation, often involving trade-offs. JAK/STAT pathway activation contributes to chronic inflammation and symptom ...

Rusfertide, a hepcidin-mimetic peptide, reduces excess red blood cell production in polycythemia vera, addressing complications like blood clots and fatigue. The FDA granted rusfertide breakthrough ...

Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low–Tumor Burden Follicular Lymphoma: Results of a LYSA Study Polycythemia vera (PV) is characterized by ...

The ongoing treatments for polycythemia vera (PV) can sometimes interfere with appetite. But if you’re getting regular blood withdrawals or undergoing chemotherapy, there’s no understating the ...

Q: My friend says his uncle is being treated for a disease where he has too much blood and he gets "bloodletting’" every other day, like in the Middle Ages. Is there really such a thing, or is he ...

For patients with a rare type of blood cancer, treatment might finally be coming out of the Dark Ages. People with the chronic condition polycythemia vera make too many red blood cells, thickening ...

Symptoms such as fatigue, itchy skin, and mental health issues can make it difficult to function, but they can be managed. “This is a chronic condition that people can live with,” says Jacqueline S.

The archaic practice of removing blood from the body to treat a wide range of illnesses lives on today as a standard treatment for certain blood disorders. The modern version of this approach, called ...